WO2001055410A3 - Ceramidase compositions and methods based thereon - Google Patents

Ceramidase compositions and methods based thereon Download PDF

Info

Publication number
WO2001055410A3
WO2001055410A3 PCT/US2001/002866 US0102866W WO0155410A3 WO 2001055410 A3 WO2001055410 A3 WO 2001055410A3 US 0102866 W US0102866 W US 0102866W WO 0155410 A3 WO0155410 A3 WO 0155410A3
Authority
WO
WIPO (PCT)
Prior art keywords
ceramidase
relates
proteins
ceramide
antibodies
Prior art date
Application number
PCT/US2001/002866
Other languages
French (fr)
Other versions
WO2001055410A9 (en
WO2001055410A2 (en
Inventor
Yusuf A Hannun
Bawab Samer El
Original Assignee
Musc Found For Res Dev
Yusuf A Hannun
Bawab Samer El
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Yusuf A Hannun, Bawab Samer El filed Critical Musc Found For Res Dev
Priority to AU2001233086A priority Critical patent/AU2001233086A1/en
Publication of WO2001055410A2 publication Critical patent/WO2001055410A2/en
Publication of WO2001055410A3 publication Critical patent/WO2001055410A3/en
Publication of WO2001055410A9 publication Critical patent/WO2001055410A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to ceramidase genes, in particular to human mitochondrial ceramidase genes and their encoded protein products, as well as derivatives and analogs thereof. Production of ceramidase proteins, derivatives, and antibodies are also provided. The present invention relates to methods for treating and preventing hyperproliferative diseases, cardiovascular diseases and inflammation based on the regulation of the level of ceramide. In particular, the invention relates to the regulation of the level of ceramide by inhibiting ceramidase expression or activity. The invention encompasses ceramidase and related nucleic acids, host cell expression systems, mutant ceramidase proteins, ceramidase fusion proteins, ceramidase antibodies, ceramidase antisense nucleic acids, and other compounds that modulate gene expression or ceramidase activity that can be used for prevention and treatment of proliferative disorders, including but not limited to breast cancer; cardiovascular diseases and inflammation.
PCT/US2001/002866 2000-01-28 2001-01-29 Ceramidase compositions and methods based thereon WO2001055410A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001233086A AU2001233086A1 (en) 2000-01-28 2001-01-29 Ceramidase compositions and methods based thereon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17897500P 2000-01-28 2000-01-28
US60/178,975 2000-01-28

Publications (3)

Publication Number Publication Date
WO2001055410A2 WO2001055410A2 (en) 2001-08-02
WO2001055410A3 true WO2001055410A3 (en) 2002-03-14
WO2001055410A9 WO2001055410A9 (en) 2002-10-17

Family

ID=22654686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002866 WO2001055410A2 (en) 2000-01-28 2001-01-29 Ceramidase compositions and methods based thereon

Country Status (2)

Country Link
AU (1) AU2001233086A1 (en)
WO (1) WO2001055410A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
MX2009004532A (en) 2006-10-27 2009-09-04 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate.
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CA2949574C (en) 2014-05-23 2022-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining whether a patient will achieve a response after radiation therapy
CN111285930B (en) * 2020-03-11 2022-02-18 北京诺思兰德生物技术股份有限公司 Nucleic acid molecule for coding parathyroid hormone protein or fragment thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044019A1 (en) * 1996-05-23 1997-11-27 Duke University Inhibitor of ceramidase
EP0890645A2 (en) * 1997-07-09 1999-01-13 Seikagaku Kogyo Kabushiki Kaisha Sialyltransferase and DNA encoding the same
WO1999035158A1 (en) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. 36 human secreted proteins
EP0980912A1 (en) * 1998-08-20 2000-02-23 Takara Shuzo Co. Ltd. Alkaline ceramidase (E.C. 3.5.1.23) gene from Pseudomonas aeruginosa
WO2000058448A1 (en) * 1999-03-26 2000-10-05 Takara Shuzo Co., Ltd. Ceramidase gene

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044019A1 (en) * 1996-05-23 1997-11-27 Duke University Inhibitor of ceramidase
EP0890645A2 (en) * 1997-07-09 1999-01-13 Seikagaku Kogyo Kabushiki Kaisha Sialyltransferase and DNA encoding the same
WO1999035158A1 (en) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. 36 human secreted proteins
EP0980912A1 (en) * 1998-08-20 2000-02-23 Takara Shuzo Co. Ltd. Alkaline ceramidase (E.C. 3.5.1.23) gene from Pseudomonas aeruginosa
WO2000058448A1 (en) * 1999-03-26 2000-10-05 Takara Shuzo Co., Ltd. Ceramidase gene

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CORONEOS EMMANUEL ET AL: "Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines: Implications for cellular proliferation and differentiation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 40, 1995, pages 23305 - 23309, XP002182184, ISSN: 0021-9258 *
DATABASE EMBL SEQUENCE LIBRARY 11 September 1997 (1997-09-11), IRANFAR, N. AND LOOMIS, W.F.: "Dictyostelium discoideum random slug cDNA25 protein (rsc25) mRNA", XP002182188 *
DATABASE EMBL SEQUENCE LIBRARY 16 April 1998 (1998-04-16), NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "ol37h09.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone similar to TR:O15913 O15913 RANDOM SLUG CDNA25 PROTEIN", XP002182186 *
DATABASE GENBANK-NCBI-DATABASE 21 October 1999 (1999-10-21), BIRREN B., LINTON L., NUSBAUM C., LANDER E.: "Homo sapiens, clone RP11-5E11", XP002182187 *
DATABASE TREMBLREL. DATABASE 1 January 1998 (1998-01-01), IRANFAR, N.: "random Slug cDNA25 protein", XP002182189 *
DATABASE WPI Section Ch Week 200059, Derwent World Patents Index; Class B04, AN 2000-619079, XP002182190 *
EL BAWAB SAMER ET AL: "Molecular cloning and characterization of a human mitochondrial ceramidase.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21508 - 21513, XP002182185, ISSN: 0021-9258 *
EL BAWAB SAMER ET AL: "Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 39, pages 27948 - 27955, XP002929691, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2001233086A1 (en) 2001-08-07
WO2001055410A9 (en) 2002-10-17
WO2001055410A2 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001001748A3 (en) Peptide compounds that bind her2
WO2005030121A3 (en) Compounds, compositions and methods
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
WO2001079443A3 (en) Albumin fusion proteins
WO2003007888A3 (en) Fat accumulation-modulating compounds
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003104270A3 (en) Dudulin genes, non-human animal model: uses in human hematological disease
WO2003060071A3 (en) Albumin fusion proteins
WO1999014346A3 (en) SENSE mRNA THERAPY
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
AU3368497A (en) Human dnase i hyperactive variants
NO20006078L (en) N-bonded sulphanamides of N-heterocyclic carboxylic acids or carboxylic acid isosters
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
ATE374251T1 (en) COMPOSITIONS FOR GENE THERAPY OF DIABETES
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2001055410A3 (en) Ceramidase compositions and methods based thereon
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
IL141325A0 (en) Tan-1057 derivatives
WO1998011234A3 (en) Human protein kinases
EP1250347A4 (en) Antisense modulation of akt-3 expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2001083450A3 (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
WO2005115461A3 (en) Pharmaceutical composition for modulating the activity of triglyceride hydrolase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP